Aardvark Therapeutics (AARD)

Its lead candidate, ARD-101, is designed as a gut-restricted agonist of specific TAS2Rs expressed in the intestinal lumen. Because the compound is intended to act locally in the gut, Aardvark’s approach seeks to address hunger signaling without relying on broad systemic exposure. The company has advanced ARD-101 into late-stage clinical development for hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder marked by persistent hunger, impaired satiety, and severe obesity risk.

Aardvark is also exploring the broader potential of its TAS2R platform in conditions where appetite control and metabolic balance are central disease drivers. This places the company within the fast-evolving metabolic disease market, but with a mechanism that differs from better-known incretin-based therapies such as GLP-1 receptor agonists. As a listed biotechnology company, Aardvark’s investment profile is closely tied to clinical trial progress, regulatory outcomes, and the ability to show that its gut-targeted biology can translate into meaningful benefits for patients with serious unmet medical needs.